Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2025)

Syndax Pharmaceuticals has reported Long-Term Investments over the past 5 years, most recently at $20.1 million for Q3 2025.

  • Quarterly results put Long-Term Investments at $20.1 million for Q3 2025, up 100.88% from a year ago — trailing twelve months through Sep 2025 was $20.1 million (up 100.88% YoY), and the annual figure for FY2024 was $119.5 million, up 300.68%.
  • Long-Term Investments for Q3 2025 was $20.1 million at Syndax Pharmaceuticals, down from $62.6 million in the prior quarter.
  • Over the last five years, Long-Term Investments for SNDX hit a ceiling of $119.5 million in Q4 2024 and a floor of $5.5 million in Q4 2022.
  • Median Long-Term Investments over the past 4 years was $20.1 million (2025), compared with a mean of $39.9 million.
  • Biggest five-year swings in Long-Term Investments: soared 445.42% in 2023 and later plummeted 36.14% in 2024.
  • Syndax Pharmaceuticals' Long-Term Investments stood at $5.5 million in 2022, then soared by 445.42% to $29.8 million in 2023, then surged by 300.68% to $119.5 million in 2024, then tumbled by 83.14% to $20.1 million in 2025.
  • The last three reported values for Long-Term Investments were $20.1 million (Q3 2025), $62.6 million (Q2 2025), and $89.9 million (Q1 2025) per Business Quant data.